1 To characterize the cysteinyl-leukotriene receptors (CysLT receptors) in isolated human pulmonary arteries, ring preparations were contracted with leukotriene C 4 (LTC 4 ) and leukotriene D 4 (LTD 4 ) in either the absence or presence of the selective CysLT 1 receptor antagonists, ICI 198615, MK 571 or the dual CysLT 1 /CysLT 2 receptor antagonist, BAY u9773. 2 Since the contractions induced by the cysteinyl-leukotrienes (cysLTs) in intact preparations failed to attain a plateau response over the concentration range studied, the endothelium was removed and the tissue treated continuously with indomethacin (Rubbed+INDO). In these latter preparations, the pEC 50 for LTC 4 and LTD 4 were not signi®cantly di erent (7.61+0.07, n=20 and 7.96+0.09, n=22, respectively). However, the LTC 4 and LTD 4 contractions were markedly potentiated when compared with data from intact tissues.3 Leukotriene E 4 (LTE 4 ) did not contract human isolated pulmonary arterial preparations. In addition, treatment of preparations with LTE 4 (1 mM; 30 min) did not modify either the LTC 4 or LTD 4 contractions. 4 Treatment of preparations with the S-conjugated glutathione (S-hexyl-GSH; 100 mM, 30 min), an inhibitor of the metabolism of LTC 4 to LTD 4 , did not modify LTC 4 contractions. 5 The pEC 50 values for LTC 4 were signi®cantly reduced by treatment of the preparations with either ICI 198615, MK 571 or BAY u9773 and the pK B values were: 7.20, 7.02 and 6.26, respectively. In contrast, these antagonists did not modify the LTD 4 pEC 50 values. 6 These ®ndings suggest the presence of two CysLT receptors on human pulmonary arterial vascular smooth muscle. A CysLT 1 receptor with a low a nity for CysLT 1 antagonists and a novel CysLT receptor subtype, both responsible for vasoconstriction. Activation of this latter receptor by LTC 4 and LTD 4 induced a contractile response which was resistant to the selective CysLT 1 antagonists (ICI 198615 and MK 571) as well as the non-selective (CysLT 1 /CysLT 2 ) antagonist, BAY u9773.